Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBoston University Charles River Campus
About this trial
This study will examine how two important brain circuits - one involving the subthalamic nucleus (STN) and one involving the ventral intermediate nucleus of the thalamus (VIM) - contribute to learning and producing speech sequences. Participants will include two groups: 1. individuals with Parkinson's disease who have deep brain stimulation (DBS) devices targeting the STN and 2. individuals with essential tremor who have DBS devices targeting the VIM.
Participants will complete speech tasks involving the learning and repetition of novel sound sequences. During some parts of the study, DBS stimulation will be temporarily turned on or off in a controlled research setting. This will allow researchers to examine how stimulation affects both the learning of new speech sequences and the production of previously learned sequences. All STN participants and most VIM participants will also be equipped with a cutting-edge DBS system, the Percept PC, which will enable the recording of deep brain activity during the tasks.
The results of this study will improve our understanding of how different brain circuits support speech learning and production. In particular, this study will help to differentiate the roles of the STN and VIM in learning the ordering of speech sounds within a syllable from learning of speech sequences containing multiple syllables. This knowledge may help guide future approaches to optimizing DBS settings to improve both movement and speech outcomes in individuals with neurological disorders, as well as provide greater general insight into how these brain structures contribute to speech production and learning.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Native speakers of American English
Adults at least 18 years of age
A clinically established diagnosis of Parkinson's disease or essential tremor
Able to provide informed consent in the judgment of the investigator
Disqualifiers
Cognitive impairment (Montreal Cognitive Assessment (MoCA; Nesreddine et al., 2005) score < 25) or active psychotic or behavioral symptoms that would, in the judgment of the investigator, preclude proper participation in the study
Hearing impairment that interferes with accurate perception of the speech motor learning stimulus (25dB hearing level threshold at 500, 1k, 2k, and 4kHz frequencies)
Language impairment (aphasia) or speech articulation impairment (dysarthria) that precludes performance of the speech motor learning task
Neurological disorder that interferes with speech motor learning
Trial design
Design model
Parallel
Treatments tested in this trial
Phoneme sequence learning
BehavioralApproximately half of subjects enrolled in the study will participate in this intervention. Subjects will read aloud monosyllabic sequences that are presented orthographically on a screen. Each sequence is formed by a non-native consonant cluster followed by a vowel and final consonant (CCVC). Speech trials will be grouped into blocks. After a Familiarization block, subjects will produce a set of twelve CCVCs in a Pretest block. Subjects will then repeatedly produce two of those CCVCs in one Training block, and two other CCVCs in a subsequent Training block. Following training, subjects will produce all four trained CCVCs and four additional novel CCVCs in each of two Test blocks. Washout blocks, during which no speech task trials are completed, will follow the Pretest, Training, and first Test block to allow subjects to rest and to complete standardized testing.
Cessation and re-enabling of stimulation of the STN
Other intervention20 adults with Parkinson's disease (PD) who have deep brain stimulator (DBS) implants in the subthalamic nucleus (STN). Stimulation of the STN will be intermittently turned off while subjects complete speech sequence learning tasks. After no more than 35 minutes, stimulation will be re-enabled with normal clinical parameters for each participant.
Cessation and re-enabling of stimulation of the VIM thalamic nucleus
Other intervention20 adults with essential tremor who have deep brain stimulator (DBS) implants in the ventral intermediate nucleus (VIM) of the thalamus will participate in this intervention. Stimulation of the VIM will be intermittently turned off (DBS OFF state) while subjects complete speech sequence learning tasks. After no more than 35 minutes, stimulation will be re-enabled with normal clinical parameters for each participant.
Multisyllabic sequence learning
BehavioralApproximately half of subjects enrolled in the study will participate in this intervention. Subjects will read aloud sequences that are presented orthographically on a screen. Speech trials will be grouped into blocks. After a Familiarization block, subjects will produce 2- and 7-syllable sequences in an Assessment block to determine the appropriate length sequence for the remainder of the intervention. Subjects will produce a set of eight sequences in a Pretest block. Subjects will then repeatedly produce two of those sequences in one Training block and two other sequences in a subsequent Training block. Following training, subjects will produce all four trained sequences and two additional novel sequences in each of two Test blocks. Washout blocks, during which no speech task trials are completed, will follow the Pretest, Training, and first Test Block to allow subjects to rest and to complete standardized testing.
Treatment groups
80 Participants
are divided into 4 treatment groupsGroup A: Subthalamic nucleus with subsyllabic learning armExperimental treatment 2 interventions
Group B: Subthalamic nucleus with multisyllabic learning armExperimental treatment 2 interventions
Group C: Ventral intermediate thalamus with subsyllabic learning armExperimental treatment 2 interventions
Group D: Ventral intermediate thalamus with multisyllabic learning armExperimental treatment 2 interventions
Trial outcomes
Primary outcomes
1
Change in speech sequencing accuracy
Investigators will evaluate recordings of speech productions to identify errors. This will be used to compare sequence accuracy before and after practice of novel sequences with DBS in the ON and OFF states.
Time frame
Day 12
Speech production duration
Investigators will inspect recordings of speech productions to identify production duration. This will be used to test hypotheses regarding differences in sequence duration before and after practice of novel sequences and with DBS in the ON and OFF states.
Time frame
Day 13
Beta power during speech production
Investigators will extract beta band (12-20 Hz) power from neural recordings taken while subjects practice and rehearse novel speech sequences. This will be used to test hypotheses regarding differences in beta power before and after practice of novel sequences and with DBS in the ON and OFF states.
Time frame
Day 1Secondary outcomes
1
Cognitive Assessment
The Montreal Cognitive Assessment (MoCa) test will be administered to all participants. Scores will be used to determine study eligibility and to identify correlations between cognitive capacity and other outcome measures. Score range: 0-30, higher score indicates higher cognitive performance.
Time frame
Baseline2
Forward Digit Span
The forward digit span subtest of the Comprehensive Test of Phonological Awareness, 2nd Edition will be administered to all participants. Scores will be used to identify correlations between working memory capacity and other outcome measures.
Time frame
Baseline3
Essential tremor severity
Participants with essential tremor will complete The Essential Tremor Rating and Assessment Scale (TETRAS) in both the DBS ON and OFF states to assess disease severity and to identify correlations between severity and other outcome measures. Score range: 0-64, lower score indicates less severe tremor.
Time frame
Day 14
Parkinson's disease severity
Part III (motor examination) of the Movement Disorder Society-sponsored revision of the Unified Parkinson's disease Ratings Scale (UPDRS part 3) will be administered to participants with Parkinson's disease in both the DBS ON and OFF states to assess disease severity and to identify correlations between severity and other outcome measures. Score range: 0-132, lower scores indicate lower motor symptom severity.
Time frame
Day 1Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Boston University Charles River Campus
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator
Massachusetts General Hospital
Collaborator
Source ClinicalTrials.gov